Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Current Deferred Revenue (2019 - 2023)

Revolution Medicines has reported Current Deferred Revenue over the past 5 years, most recently at $1.4 million for Q1 2023.

  • Quarterly results put Current Deferred Revenue at $1.4 million for Q1 2023, down 87.46% from a year ago — trailing twelve months through Mar 2023 was $1.4 million (down 87.46% YoY), and the annual figure for FY2022 was $4.5 million, down 63.92%.
  • Current Deferred Revenue for Q1 2023 was $1.4 million at Revolution Medicines, down from $4.5 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for RVMD hit a ceiling of $17.1 million in Q4 2019 and a floor of $1.4 million in Q1 2023.
  • Median Current Deferred Revenue over the past 5 years was $11.8 million (2020), compared with a mean of $11.0 million.
  • Biggest five-year swings in Current Deferred Revenue: increased 16.18% in 2022 and later tumbled 87.46% in 2023.
  • Revolution Medicines' Current Deferred Revenue stood at $17.1 million in 2019, then fell by 29.27% to $12.1 million in 2020, then increased by 2.04% to $12.4 million in 2021, then plummeted by 63.92% to $4.5 million in 2022, then plummeted by 67.84% to $1.4 million in 2023.
  • The last three reported values for Current Deferred Revenue were $1.4 million (Q1 2023), $4.5 million (Q4 2022), and $9.7 million (Q3 2022) per Business Quant data.